MiNK Therapeutics, Inc.

Hello, everyone, and welcome to Mink Therapeutics' fourth quarter 2024 financial results call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session. If you'd like to ask a question during that time, please press star followed by one on your telephone keypad. Thank you. I'd now like to hand the call over to Zach Arman, Investor Relations. You may now begin.

Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory, and commercial plans, timelines for data release, and partnership opportunities. These statements are subject to risk and uncertainty. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, and Christine Klaskin, Principal Financial and Accounting Officer.

Now, I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter.